Rona Karahoda1, Hana Horackova1, Petr Kastner2, Andreas Matthios3, Lukas Cerveny1, Radim Kucera2, Marian Kacerovsky4, Jurjen Duintjer Tebbens3, Alexandre Bonnin5, Cilia Abad1, Frantisek Staud1. 1. Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Charles University, Hradec Kralove, Czech Republic. 2. Faculty of Pharmacy in Hradec Kralove, Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Charles University, Hradec Kralove, Czech Republic. 3. Faculty of Pharmacy in Hradec Kralove, Department of Biophysics and Physical Chemistry, Charles University, Hradec Kralove, Czech Republic. 4. Department of Gynecology and Obstetrics, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic. 5. Department of Physiology and Neuroscience, University of Southern California, Los Angeles, CA, USA.
Abstract
AIM: Serotonin is crucial for proper foetal development, and the placenta has been described as a 'donor' of serotonin for the embryo/foetus. However, in later stages of gestation the foetus produces its own serotonin from maternally-derived tryptophan and placental supply is no longer needed. We propose a novel model of serotonin homeostasis in the term placenta with special focus on the protective role of organic cation transporter 3 (OCT3/SLC22A3). METHODS: Dually perfused rat term placenta was employed to quantify serotonin/tryptophan transport and metabolism. Placental membrane vesicles isolated from human term placenta were used to characterize serotonin transporters on both sides of the syncytiotrophoblast. RESULTS: We obtained the first evidence that serotonin is massively taken up from the foetal circulation by OCT3. This uptake is concentration-dependent and inhibitable by OCT3 blockers of endogenous (glucocorticoids) or exogenous (pharmaceuticals) origin. Population analyses in rat placenta revealed that foetal sex influences placental extraction of serotonin from foetal circulation. Negligible foetal serotonin levels were detected in maternal-to-foetal serotonin/tryptophan transport and metabolic studies. CONCLUSION: We demonstrate that OCT3, localized on the foetus-facing membrane of syncytiotrophoblast, is an essential component of foeto-placental homeostasis of serotonin. Together with serotonin degrading enzyme, monoamine oxidase-A, this offers a protective mechanism against local vasoconstriction effects of serotonin in the placenta. However, this system may be compromised by OCT3 inhibitory molecules, such as glucocorticoids or antidepressants. Our findings open new avenues to explore previously unsuspected/unexplained complications during pregnancy including prenatal glucocorticoid excess and pharmacotherapeutic risks of treating pregnant women with OCT3 inhibitors.
AIM: Serotonin is crucial for proper foetal development, and the placenta has been described as a 'donor' of serotonin for the embryo/foetus. However, in later stages of gestation the foetus produces its own serotonin from maternally-derived tryptophan and placental supply is no longer needed. We propose a novel model of serotonin homeostasis in the term placenta with special focus on the protective role of organic cation transporter 3 (OCT3/SLC22A3). METHODS: Dually perfused rat term placenta was employed to quantify serotonin/tryptophan transport and metabolism. Placental membrane vesicles isolated from human term placenta were used to characterize serotonin transporters on both sides of the syncytiotrophoblast. RESULTS: We obtained the first evidence that serotonin is massively taken up from the foetal circulation by OCT3. This uptake is concentration-dependent and inhibitable by OCT3 blockers of endogenous (glucocorticoids) or exogenous (pharmaceuticals) origin. Population analyses in rat placenta revealed that foetal sex influences placental extraction of serotonin from foetal circulation. Negligible foetal serotonin levels were detected in maternal-to-foetal serotonin/tryptophan transport and metabolic studies. CONCLUSION: We demonstrate that OCT3, localized on the foetus-facing membrane of syncytiotrophoblast, is an essential component of foeto-placental homeostasis of serotonin. Together with serotonin degrading enzyme, monoamine oxidase-A, this offers a protective mechanism against local vasoconstriction effects of serotonin in the placenta. However, this system may be compromised by OCT3 inhibitory molecules, such as glucocorticoids or antidepressants. Our findings open new avenues to explore previously unsuspected/unexplained complications during pregnancy including prenatal glucocorticoid excess and pharmacotherapeutic risks of treating pregnant women with OCT3 inhibitors.
Authors: Claire L Townsend; Laura Byrne; Mario Cortina-Borja; Claire Thorne; Annemiek de Ruiter; Hermione Lyall; Graham P Taylor; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2014-04-24 Impact factor: 4.177
Authors: Anne Amphoux; Vincent Vialou; Eva Drescher; Michael Brüss; Clotilde Mannoury La Cour; Catherine Rochat; Mark J Millan; Bruno Giros; Heinz Bönisch; Sophie Gautron Journal: Neuropharmacology Date: 2006-03-31 Impact factor: 5.250
Authors: H Kono; Y C Lin; M Yamaguchi; F P Zuspan; R W O'Shaughnessy; A C Lee; N Furuhashi; T Yokaichiya; K Takayama; A Yajima Journal: Tohoku J Exp Med Date: 1994-01 Impact factor: 1.848
Authors: Harvey J Kliman; Sarah B Quaratella; Alessandra C Setaro; Erin C Siegman; Zarrin T Subha; Reshef Tal; Kristin M Milano; Theodore L Steck Journal: Endocrinology Date: 2018-04-01 Impact factor: 4.736
Authors: Rheaclare Fraser-Spears; Anwen M Krause-Heuer; Mohamed Basiouny; Felix P Mayer; Retrouvailles Manishimwe; Naomi A Wyatt; Jeremy C Dobrowolski; Maxine P Roberts; Ivan Greguric; Naresh Kumar; Wouter Koek; Harald H Sitte; Paul D Callaghan; Benjamin H Fraser; Lynette C Daws Journal: Eur J Pharmacol Date: 2018-10-25 Impact factor: 5.195
Authors: Aarthi R Gobinath; Joanna L Workman; Carmen Chow; Stephanie E Lieblich; Liisa A M Galea Journal: Biol Sex Differ Date: 2017-06-02 Impact factor: 5.027
Authors: Georgianna G Gould; Priscilla A Barba-Escobedo; Rebecca E Horton; Lynette C Daws Journal: Front Pharmacol Date: 2022-06-09 Impact factor: 5.988
Authors: Rafael R Domingues; Hannah P Fricke; Celeste M Sheftel; Autumn M Bell; Luma C Sartori; Robbie S J Manuel; Chandler J Krajco; Milo C Wiltbank; Laura L Hernandez Journal: Toxics Date: 2022-01-01